Solstice Oncology raises $225M Series A to push next-gen CTLA-4 antibody into Phase 2 colon cancer trial
Solstice Oncology announced a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners and Forbion.
The capital will fund the Phase 2 study of its Fc-enhanced CTLA-4 antibody, porustobart, which the company licensed from Harbour BioMed, targeting microsatellite stable stage II and III colon cancer, a patient group that has not responded to existing immunotherapies.
The trial will combine porustobart with Keytruda, begin enrollment this year, and is slated for a readout in the second half of 2027. Solstice also intends to explore the antibody in an additional, undisclosed indication.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that